Design Therapeutics, Inc.
NASDAQ:DSGN
5.54 (USD) • At close September 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Design Therapeutics, Inc. |
Symbool | DSGN |
Munteenheid | USD |
Prijs | 5.54 |
Beurswaarde | 313,677,570 |
Dividendpercentage | 0% |
52-weken bereik | 1.96 - 6.91 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Pratik Shah Ph.D. |
Website | https://www.designtx.com |
An error occurred while fetching data.
Over Design Therapeutics, Inc.
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)